@article{ATM30081,
author = {Helen Adderley and Christoph Jakob Ackermann and Raffaele Califano},
title = {Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 8},
year = {2019},
keywords = {},
abstract = {EGFR tyrosine kinase inhibitors (TKIs) represent the standard of care for first-line treatment for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC) with superiority in overall response rate (ORR), progression free survival (PFS) and quality of life compared to platinum-based chemotherapy (ChT) (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/30081}
}